Cochrane · systematic review · CD012983
Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs
Gonzalez Garay, AG, Molano Franco, D, Nieto Estrada, VH, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Emergency and Critical CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
9
No studies
7
Included studies
NR
No studies 7 · 43.8%Ungraded 0 · 0%Very low 1 · 6.3%Low 8 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Sumatriptan compared with placebo for preventing high altitude illness
Population: participants at risk of high altitude illness
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Risk of acute mountain sickness Sumatriptan vs placebo | RR 0.43 [0.21, 0.84] | 1 study · 102 participants | Low Downgraded: imprecision |
Risk of high altitude pulmonary oedema ‐ not reported Sumatriptan vs placebo | no estimate extracted | NR | No studies |
Risk of high altitude cerebral oedema ‐ not reported Sumatriptan vs placebo | no estimate extracted | NR | No studies |
Risk of adverse events ‐ not reported Sumatriptan vs placebo | no estimate extracted | NR | No studies |
Magnesium citrate compared with placebo for preventing high altitude illness
Population: participants at risk of high altitude illness
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Risk of acute mountain sickness Magnesium citrate vs placebo | RR 1.09 [0.55, 2.13] | 1 study · 70 participants | Low Downgraded: imprecision |
Risk of high altitude pulmonary oedema‐ not reported Magnesium citrate vs placebo | no estimate extracted | NR | No studies |
Risk of high altitude cerebral oedema‐ not reported Magnesium citrate vs placebo | no estimate extracted | NR | No studies |
Risk of adverse events: Loose stools Magnesium citrate vs placebo | RR 3.25 [1.17, 8.99] | 1 study · 70 participants | Low Downgraded: imprecision |
Spironolactone compared with placebo for preventing high altitude illness
Population: participants at risk of high altitude illness
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Risk of acute mountain sickness Spironolactone vs placebo | no estimate extracted | 2 studies · 205 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Risk of high altitude pulmonary oedema Spironolactone vs placebo | no estimate extracted | 1 study · 193 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Risk of High altitudecerebral oedema Spironolactone vs placebo | no estimate extracted | 1 study · 193 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Risk of adverse events ‐ not reported Spironolactone vs placebo | no estimate extracted | NR | No studies |
Acetazolamide compared with spironolactone for preventing high altitude illness
Population: participants at risk of high altitude illness
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Risk of acute mountain sickness Acetazolamide vs spironolactone | RR 0.36 [0.18, 0.7] | 1 study · 232 participants | Low Downgraded: risk of bias, imprecision |
Risk of high altitude pulmonary oedema Acetazolamide vs spironolactone | no estimate extracted | 1 study · 232 participants | Low Downgraded: risk of bias, imprecision |
Risk of high altitude cerebral oedema Acetazolamide vs spironolactone | no estimate extracted | 1 study · 232 participants | Low Downgraded: risk of bias, imprecision |
Risk of adverse events ‐ not reported Acetazolamide vs spironolactone | no estimate extracted | NR | No studies |